Adoptive CD8+ T-cell therapy - Merck Sharp and Dohme/MD Anderson Cancer Center

Drug Profile

Adoptive CD8+ T-cell therapy - Merck Sharp and Dohme/MD Anderson Cancer Center

Alternative Names: Adoptive T-cell infusion; CD8+ T-cell therapy

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Mar 2017 University of Texas M.D. Anderson Cancer Center plans a phase I trial for Uveal melanoma (Metastatic disease) in USA (NCT03068624)
  • 28 Oct 2016 Preclinical trials in Solid tumours in USA (Infusion) before October 2016
  • 08 Sep 2016 Merck Sharp and Dohme plans a phase I trial for Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02757391)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top